Fate Therapeutics (FATE) Tops Q2 EPS by 1c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $1 million versus the consensus estimate of $940 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Is Treasury selloff a major issue for stock market bulls?
• INVO Fertility (IVF) Tops Q2 EPS by 105c